After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.
|
|
- Lucinda Malone
- 5 years ago
- Views:
Transcription
1 New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs are skyrocketing. Miraculins Inc. has two hot products for medical testing While the company s opening market focus is targeted for North America, they have signed a new $90 million sales and distribution agreement in China for one of its two propritary products offering non-invasive testing for diabetes. After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up. A technical chart double price bottom is bullish. It gets even better when those price bases are further spread out in June and November as we see on the following chart. The stock price on Wednesday January 7, 2014 is C$.24. Our technical price forecast for the shares during 2015 is C$.83 In our view this is not a trading stock for now. Trader Tracks recommends a buy and hold with a time cycle of at least 6-12 months and perhaps longer. This company, based upon offered products, is addressing huge mass international markets that could have a long way to go in both price and earnings.
2 One year chart for MOM shows a solid trading range from C$.10 to C$.45. The medical device company is offering investors a chance to enter and hold for what we believe could be excellent gains. Miraculins at a Glance Miraculins is a biotechnology company that acquires develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The company s lead technology programs the Scout DS Diabetes Screen and the PreVu Skin Cholesterol Test are point-of-care tests that screen for risk of diabetes and coronary artery disease respectively, without needles, blood draw, fasting or waiting. Patients with elevated test results are then recommended to see their physicians for follow-up. The Scout DS is a ground-breaking, non-invasive diabetes-screening device that uses visible light to fluoresce, detect and measure biomarkers present in the skin associated with pre-diabetes and type 2 diabetes and takes only 90 seconds. The PreVu Non-Invasive Skin Cholesterol Point-of-Care (POC) Test measures cholesterol in the skin as a new risk marker for coronary artery disease, without requiring needles, blood draw or fasting... in less than 5 minutes Both of these technologies are totally non-invasive and user-friendly, characteristics that can encourage individuals to get screened early and often for risk of pre-diabetes and type 2 diabetes - now being referred to by experts as the fastest growing disease in history - and risk of coronary artery disease, for which diabetes is also a major risk factor.
3 On August 14, 2014, the Company announced that it had executed a definitive agreement for the sale and distribution of Scout DS diabetes screening devices into China with Catalyn Medical Technologies Limited, a privately-owned and Hong Kong based medical device import Company. It was also announced that Cachet Pharmaceutical Co., Ltd. had been co-appointed as the exclusive distributor of the Scout DS devices in Mainland China by Miraculins and Catalyn. The agreement allows for the sale and distribution of up to $90 Million USD in Scout DS Diabetes Screening Devices in Mainland China, over the length of the 5-year agreement term. Miraculins, Inc. a Canadian biotechnology company (MOM) has 20,228,000 shares outstanding with a market cap of 10 million. The 52 week high was posted on January 7, The 52 week low was posted on June 9, The average price for 50 days is C$.15 and for 200-days is C$.16. Volumes for 50-day average 62,036 and for 200-days 45,549. Miraculins Completes Amendment to 2013 Scout DS Asset Purchase Agreement with VeraLight December 23, 2014 company website WINNIPEG, Manitoba December 23, Miraculins Inc. (TSX-V:MOM) (the Company ), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has executed an amendment (the Amendment ) with VeraLight, Inc. ( VeraLight ) to the asset purchase agreement dated June 28, 2013 between Miraculins and VeraLight (the APA ), wherein Miraculins acquired all of the relevant assets relating to VeraLight s Scout DS non-invasive diabetes screening technology. The Amendment eliminates the
4 majority of the Company s remaining obligations and terminates the obligation to issue equity to VeraLight under APA. In connection with the Amendment, the Company has made a one-time payment of CDN $500,000 to VeraLight. In addition to the one-time payment, the Company has issued 1,000,000 new common share purchase warrants (the Warrants ) to VeraLight at an exercise price of CDN $0.25 per share with a term expiring on the fifth anniversary after issuance. Of these, 450,000 of the Warrants will vest immediately and the remaining 550,000 Warrants will vest upon the earlier of (i) 12 months from the date of issuance, or (ii) a Liquidity Event (as defined below). No common shares or warrants have previously been issued to VeraLight, and on the closing of the Agreement, VeraLight will have no right to receive common shares of the Company other than the Warrants described above. With the recent announcement of our USD$90 Million sales and distribution agreement for Scout DS in China, and our strong belief in the technology s growing potential, we entered into discussions with VeraLight to amend the asset purchase agreement, said Christopher J. Moreau, President and Chief Executive Officer for Miraculins Inc. In addition to terminating our obligation to provide Veralight with equity under the APA, the Amendment has eliminated the Company s obligations related to spending on ScoutDS related activities, adherence to certain manufacturing commitments and reporting obligations related to Scout DS, the appointment of a VeraLight nominee to the Company s Board, and also terminates VeraLight s first ranking security on all APA assets. company website Scout DS and PreVu Market Potential Miraculins believes that the key to bringing these numbers down is earlier screening bringing diabetes and heart disease through the introduction of non-invasive, user-friendly and rapid screening technologies that will encourage individuals to take a few minutes out of their busy days, in convenient settings, to get tested and educated about their potential risk. The goal of the Miraculins screening technologies is to provide patients at risk with an early distance warning and to serve as a tipping point for individuals to take real-time action and follow-up with their healthcare providers for immediate, effective and ongoing management of their conditions, whatever the stage. Screening allows for faster, earlier testing and greater patient turnaround, as well as a pain free alternative that doesn t require needles, fasting, blood work, or waiting. Widespread access to these new and innovative technologies which are also highly mobile, affordable, and cost-effective - could significantly increase early screenings worldwide, leading to positive impacts for patients, physicians, and the healthcare economy overall. The Company s commercialization strategy is global in vision and includes leasing and selling its Scout DS and PreVu medical devices and consumables to hospitals, clinics and physician s offices; retail testing through stand-alone kiosks in pharmacies/grocery chains; and workplace health screenings through companies of various sizes in both the private and public sectors, as well as through government employers. Pharmacies and grocery chains are expected to be quite responsive, for instance, in that the average prediabetic and diabetic patient can generate up to $800 and $3,000 per year in revenue, respectively. Workplace screenings can also additionally help companies better manage their employees health and wellness, realize lower disability and medical claims, and enhance efficiencies which are significant motivations to participation in screening programs as well. In the long term, the Company also intends to
5 build its case for government/private insurance reimbursement in multiple markets, and believes that CPT codes already exist in the U.S. to cover the Scout DS test in physician s offices, on procurement of FDA clearance for the device. -website Some very beneficial key points we see for this company and its products Miraculins is addressing two very high demand healthcare needs, with their screening tests locked into a long term growth mode as a result. Those being diabetes risk screening in the USA alone there are 30 million type-2 diabetics (1 in 4 don t know it) and 86 million pre-diabetics (9 in 10 don t know it) - and screening for risk of coronary artery disease, which is the number one killer of American men and women and is the leading cause of premature, permanent disability in the United States labor force. I can see serious growth for these products as medical plans in Canada and America are going into overload with limited personnel and sky rocketing expenses. These devices enable quick tests in doctor s offices and other accessible channels that can be performed every 1-3 years towards ongoing risk assessment and to assist with earlier disease detection. In a recent conference call with the CEO we learned of the strong clinical data behind the devices underscoring their utilities, which in our view is paramount. As the news of these products is more widespread and recognized, the increased visibility will promote better global medical care and in our view, a boost for the shares. The Chinese agreement provides Miraculins with a gateway entry in Asian markets that might be larger in sales scope than North America. For Investor Relations: Telephone or ir@miraculins.com Miraculins Inc., Waverley Street, Winnipeg, Manitoba R3T 6C6 Telephone: Fax: info@miraculins.com Copyright by Wavelength Publishing LLC. No reproduction of this material is allowed without publisher permission.
Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationMexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationAsia-Pacific Electrophysiology Market Outlook to 2020
Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationMalaria Initiative: Access
Novartis Social Business Malaria Initiative: Access Improving affordability and availability of medicines Over the past decade, the Novartis Malaria Initiative has pioneered the pharmaceutical response
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationThe Danish Medicines Agency s availability strategy
låst DECEMBER 2016 The Danish Medicines Agency s availability strategy 2017 2021 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source. Images
More informationThe Value of Walgreens
The Value of Walgreens How Walgreens improves employer health plans through access, quality and lower costs Why millions of patients choose Walgreens And your options to move forward with Walgreens Walgreens
More informationHeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017
HeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017 Key Messages Message 1: Diagnostic Gap Detection of Asymptomatic Patients Physicians do not have
More informationCutanea Life Sciences, Inc. Comprehensive Compliance Program
Cutanea Life Sciences, Inc. Comprehensive Compliance Program Cutanea engages in research, development, manufacture and marketing of dermatology products, including commercialization of those products.
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Today s Speakers John Figueroa Chief Executive Officer Vic Breed Chief Financial Officer Joined Genoa in July 2014 Previously served the dual roles of CEO of Apria
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationChina Interventional Cardiovascular Device Industry Report, Jan. 2011
China Interventional Cardiovascular Device Industry Report, 2010 Jan. 2011 This report analyzes the social, economic and policy environments, the overall operation, market competition and development trends
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationPolicy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: Address: (name) Mark Forsyth (street/box number) 3 Queens Wharf (town/city)
More informationNoninvasive Glucose Monitors to 2022
Noninvasive Glucose Monitors to 2022 Devices, Technologies, Players and Prospects Report Prospectus Greystone Research associates N o n i n v a s i v e G l u c o s e M o n i t o r s t o 2 0 2 2 Greystone
More informationCannabis Regulation in Canada:
Cannabis Regulation in Canada: Where We Came From, Where We Are and What s Coming Next Jonathan Sherman Cassels Brock & Blackwell LLP Sherri Altshuler Aird & Berlis LLP Canada, In Brief Right Now... Legal
More informationSegment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More information2006 Annual Report. Anastomosis Made Simple
2006 Annual Report R Anastomosis Made Simple Cardica designs and manufactures proprietary automated anastomosis systems used by surgeons to perform rapid, reliable and consistent connections, or anastomoses,
More informationVolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused
More informationInstitute of Medicine (IOM) Consensus Study on Accessible and Affordable Hearing Health Care for Adults
Institute of Medicine (IOM) Consensus Study on Accessible and Affordable Hearing Health Care for Adults Hearing Loss Association of America Anna Gilmore Hall April 27, 2015 I got a hearing aid and it is
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationRussia Cardiac Assist Devices Market Outlook to 2021
Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected publishers for
More informationNoninvasive Glucose Monitors Devices, Technologies, Players and Prospects
Report Prospectus Noninvasive Glucose Monitors Devices, Technologies, Players and Prospects 1 Improving Diabetes Management For diabetes patients, glucose monitoring is a way of life, a several-times-per-day
More informationHalton Region. Business Conditions
Halton Region Business Conditions 2014 Message from Regional Chair Gary Carr Time and again, innovative business owners in Halton tell me that Halton is a great place to live and work because we offer
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationAssessing private expenditures in HIV/AIDS: methods, tools, examples
Assessing private expenditures in HIV/AIDS: methods, tools, examples Dr Ravi P. Rannan-Eliya Targeted programs financing and budgeting for HIV/AIDS Seminar Yalta Hotel, Yalta, Crimea, Ukraine 19 July 2007
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210
ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 Price- $6,330,275 Cap Rate-5.45% Absolute Net Lease with 19 Years Remaining on Initial Lease Term. Lease Guaranteed by Walgreen
More informationeclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Projected to grow at a CAGR of around 12%, eclinical solutions market is expected to witness significant
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationChina Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
More informationChina Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationASX Announcement 22 June 2017
ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationBlood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595
Transparency Market Research Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample
More informationCommunity-Based Point-of-Care Testing: From Innovative Care Model to Common Practice
Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice Donald G. Klepser, PhD, MBA Associate Professor University of Nebraska Medical Center Brian Bobby Rite Aid Vice President,
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationPandemic Flu: Preplanning for an Outbreak
Pandemic Flu: Preplanning for an Outbreak Presented to AACRAO Leta Finch Executive Director, Higher Education Practice Group Arthur J. Gallagher Risk Management Services, Inc. 2006 Arthur J. Gallagher
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationRULES OF CONDUCT OF INSIDERS RESPECTING
T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationAlmirall grants Invida commercial rights for Aclidinium in Australia and New ZealandAlmirall????? (Invida)??????????? Aclidinium?????
Almirall grants Invida commercial rights for Aclidinium in Australia and New ZealandAlmirall????? (Invida)??????????? Aclidinium????? Almirall licenses Aclidinium to Invida in Australia and New Zealand
More informationMexico Milling Machine for Dental Clinics Industry 2016 Market Research Report
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Mexico Milling Machine for Dental Clinics Industry Market Research Report Mexico Milling Machine for Dental Clinics
More informationItamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationWorldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015
Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015 LEXINGTON, Massachusetts (March 14, 2009) WinterGreen Research announces that it has a new study on Worldwide nanotechnology dental
More informationChapter 1: Executive Summary
Chapter 1: Executive Summary Definition, Scope, and Methodology Related Terms Functional Foods Nutraceuticals Foods for Special Dietary Use Condition-specific Nutritional Supplements Medical Foods Medical
More informationWALGREENS DRONE FOOTAGE AVAILABLE. Absolute NNN Lease Investment Opportunity. 758 N Ellington Parkway Lewisburg, TN
WALGREENS 758 N Ellington Parkway Lewisburg, TN Absolute NNN Lease Investment Opportunity Click here to view drone footage of the property! DRONE FOOTAGE AVAILABLE STUART FRANKEL PRESIDENT NET LEASED DIVISION
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More informationCannabis use carries significant health risks, especially for people who use it frequently and or/begin to use it at an early age.
Background: The Centre for Addiction and Mental Health (CAMH) released recommendations for the Legalization of Marijuana (with restrictions and regulations) on October 8, 2014. Addiction Services of Thames
More informationGlobal Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationIndonesia-Intensified Iodine Deficiency Control Project. Ministry of Health (MOH)/Ministry of Industry (MOI)
Project Name Region Sector Project ID Implementing Agency Report No. PIC2866 Indonesia-Intensified Iodine Deficiency Control Project East Asia and Pacific Population and Human Resources IDPA42450 Ministry
More informationASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE
ASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE SYDNEY, Tuesday, 20 November 2012: Cellmid Limited (ASX: CDY) CEO, Maria Halasz, will present today at the Wholesale Investor Conference,
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationNET LEASE INVESTMENT OFFERING RITE AID PHARMACY
RITE AID PHARMACY 11702 Lorain Avenue Cleveland, OH 44111 TABLE OF CONTENTS TABLE OF CONTENTS I. Executive Profile Executive Summary Investment Highlights Property Overview II. Location Overview Photographs
More informationSample Pages. Needlestick Safety Injection Devices Market, Copyright 2012 Banyan Wharf Consultants Ltd. Page 1
Sample Pages Needlestick Safety Injection Devices Market, 2014-2024 Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 This page is intentionally left blank Copyright 2014 Roots Analysis Private Ltd.
More informationFOR IMMEDIATE RELEASE: Media Alert:
FOR IMMEDIATE RELEASE: Media Alert: 1-Source/AMP-RTI Unveils Design, application, system and product development of SGD For Aphasic Speech Pathology Segment for O Brien Technologies, Inc. Lenoir, NC &
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationHot Topics in Healthcare Osher Lifelong Learning Institute University of California at San Diego. October 17, 2017
Hot Topics in Healthcare Osher Lifelong Learning Institute University of California at San Diego October 17, 2017 Format Notes Speakers present pro and con perspectives Goal is to inform..not have one
More informationUltrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to Hexa Research
Ultrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to 2024 - Hexa Research " The global ultrasound device market was valued at approximately USD 6.8 billion and it is projected
More informationMarketing Health and Nutrition: Does it Work?
Marketing Health and Nutrition: Does it Work? Julie G. Adams Almond Board of California 14 June 2011 1 Case Study in less than 15 minutes! Why demand creation is a must, not an option, for almonds Capitalizing
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationEurope Tooth Shade Scanners Industry 2016 Market Research Report
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Tooth Shade Scanners Industry Market Research Report Europe Tooth Shade Scanners Industry Market Research
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationFinancing for Family Planning: Options and Challenges
Repositioning Family Planning and Reproductive Health in the region. Financing for Family Planning: Options and Challenges BASINGA Paulin, MD,MSc, PhD Senior Lecturer School of Public Health National University
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationSupplier Code of Business Conduct
Supplier Code of Business Conduct We act with integrity, honesty and respect. Sempra Energy Values We are an ethical, respectful, high performing, forward looking, responsible partner. Our values define
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationFlexi-Needles. BMI_FLEXINEEDLES_v2 web
Flexi-Needles BMI_FLEXINEEDLES_v2 _ _web Best Medical can provide any standard or customized configuration made to your exact specifications, sterile or non-sterile, shipped within 24 hours worldwide!
More information